# James O'Mara

> James (Jim) O'Mara is the President and CEO of Neurogastrx, a Woburn, Massachusetts specialty pharmaceutical company developing oral therapies for gastrointestinal disorders. A pharmacist by training with decades in biotech, he was one of the original members of the LINZESS team at Ironwood Pharmaceuticals, where he rose to Senior Vice President of Corporate Development and drove licensing deals across the U.S., Europe, Japan and China. At Neurogastrx he raised a $60 million Series B and is steering the company's lead candidate, NG101, through clinical studies aimed at the nausea and vomiting that lead many patients to abandon GLP-1 weight-loss and diabetes medicines.

- **Role:** President and CEO at Neurogastrx, Inc.
- **Organizations:** Neurogastrx, Inc., Ironwood Pharmaceuticals, Cozint Interactive, MPM Capital
- **Nationality:** American
- **Education:** B.S. in Pharmacy, Massachusetts College of Pharmacy and Health Sciences
- **Known for:** Raised $60 million Series B financing for Neurogastrx in 2021 (part of $125M total funding), Reassembled a veteran ex-Ironwood management team to build out Neurogastrx's pipeline, Was an original member of the LINZESS team at Ironwood, a leading IBS therapy

## Career timeline

- **Early career** — Vice President at MPM Capital, focusing on business development transactions for emerging biotech companies
- **Mid career** — Vice President of Corporate Development at Cozint Interactive, one of the first online market intelligence companies
- **2000s-2010s** — Original member of the LINZESS team at Ironwood Pharmaceuticals; led commercial profile development and international licensing deals across the US, Europe, Japan and China
- **Departure** — Left Ironwood Pharmaceuticals as Senior Vice President of Corporate Development
- **2021** — As President and CEO of Neurogastrx, secured $60 million Series B financing and expanded the management team
- **2024** — Announced positive proof-of-concept data for NG101 in reducing GLP-1-associated nausea and vomiting
- **2025** — Announced Phase 2 clinical study results for NG101 showing significant reductions in nausea and vomiting induced by semaglutide

## Achievements

- Raised $60 million Series B financing for Neurogastrx in 2021 (part of $125M total funding)
- Reassembled a veteran ex-Ironwood management team to build out Neurogastrx's pipeline
- Was an original member of the LINZESS team at Ironwood, a leading IBS therapy
- Directed international licensing deals for LINZESS across the US, Europe, Japan and China
- Advanced lead candidate NG101 through positive proof-of-concept and Phase 2 studies targeting GLP-1-associated nausea

## Latest updates

- **2025-11** — Neurogastrx announced Phase 2 clinical study results showing NG101 significantly reduced nausea and vomiting induced by the GLP-1 receptor agonist semaglutide, including a 67% reduction in vomiting incidence.
- **2024-10** — Neurogastrx announced positive proof-of-concept data for NG101 in reducing GLP-1-associated nausea and vomiting, with plans for a larger Phase 2/3 study.

## Links

- Website: https://neurogastrx.com
- LinkedIn: http://www.linkedin.com/in/james-j-omara

---

Profile page: https://yespress.io/james-o-mara
Published by YesPress — https://yespress.io
Last updated: 2026-07-16